Combotope Therapeutics Enters into Collaboration with Boehringer Ingelheim to Advance First-in-Class Tumor-Selective Antibody Therapies for Cancer

Collaboration spans multiple oncology targets and combines Combotope's SMART-Phage™ discovery platform with Boehringer Ingelheim's research and development expertise. Dual recognition of a cancer-linked sugar pattern and its protein carrier enables highly tumor-selective antibody...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.